Gilead Sciences EPS History: Annual & Quarterly (GILD)
Gilead Sciences's diluted EPS was $6.78 for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.78 | $6.84 | $6.40 | +1684.21% |
| 2024 | 2024-12-31 | $0.38 | $0.38 | -$4.12 | −91.56% |
| 2023 | 2023-12-31 | $4.50 | $4.54 | $0.86 | +23.63% |
| 2022 | 2022-12-31 | $3.64 | $3.66 | -$1.29 | −26.17% |
| 2021 | 2021-12-31 | $4.93 | $4.96 | $4.83 | +4830.00% |
| 2020 | 2020-12-31 | $0.10 | $0.10 | -$4.12 | −97.63% |
| 2019 | 2019-12-31 | $4.22 | $4.24 | $0.05 | +1.20% |
| 2018 | 2018-12-31 | $4.17 | $4.20 | $0.66 | +18.80% |
| 2017 | 2017-12-31 | $3.51 | $3.54 | -$6.43 | −64.69% |
| 2016 | 2016-12-31 | $9.94 | $10.08 | -$1.97 | −16.54% |
| 2015 | 2015-12-31 | $11.91 | $12.37 | $4.56 | +62.04% |
| 2014 | 2014-12-31 | $7.35 | $7.95 | $5.54 | +306.08% |
| 2013 | 2013-12-31 | $1.81 | $2.01 | $0.17 | +10.37% |
| 2012 | 2012-12-31 | $1.64 | $1.71 | -$0.13 | −7.34% |
| 2011 | 2011-12-31 | $1.77 | $1.81 | $0.11 | +6.63% |
| 2010 | 2010-12-31 | $1.66 | $1.69 | $0.25 | +17.73% |
| 2009 | 2009-12-31 | $1.41 | $1.46 | $0.38 | +36.89% |
| 2008 | 2008-12-31 | $1.03 | $1.08 | $0.21 | +25.61% |
| 2007 | 2007-12-31 | $0.82 | $0.86 | — | — |
Gilead Sciences quarterly diluted eps
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$8.45 | -$8.45 | -$10.01 | — |
| Q1 2026 | 2026-03-31 | $1.61 | $1.63 | $0.57 | +54.81% |
| Q4 2025 | 2025-12-31 | $1.74 | $1.76 | — | — |
| Q3 2025 | 2025-09-30 | $2.43 | $2.46 | $1.43 | +143.00% |
| Q2 2025 | 2025-06-30 | $1.56 | $1.57 | $0.27 | +20.93% |
| Q1 2025 | 2025-03-31 | $1.04 | $1.06 | $4.38 | — |
| Q3 2024 | 2024-09-30 | $1.00 | $1.00 | -$0.73 | −42.20% |
| Q2 2024 | 2024-06-30 | $1.29 | $1.29 | $0.46 | +55.42% |
| Q1 2024 | 2024-03-31 | -$3.34 | -$3.34 | -$4.14 | — |
| Q3 2023 | 2023-09-30 | $1.73 | $1.75 | $0.31 | +21.83% |
| Q2 2023 | 2023-06-30 | $0.83 | $0.84 | -$0.08 | −8.79% |
| Q1 2023 | 2023-03-31 | $0.80 | $0.81 | $0.78 | +3900.00% |
| Q3 2022 | 2022-09-30 | $1.42 | $1.43 | -$0.63 | −30.73% |
| Q2 2022 | 2022-06-30 | $0.91 | $0.91 | -$0.30 | −24.79% |
| Q1 2022 | 2022-03-31 | $0.02 | $0.02 | -$1.35 | −98.54% |
| Q3 2021 | 2021-09-30 | $2.05 | $2.06 | $1.76 | +606.90% |
| Q2 2021 | 2021-06-30 | $1.21 | $1.21 | $3.87 | — |
| Q1 2021 | 2021-03-31 | $1.37 | $1.38 | $0.15 | +12.30% |
| Q4 2020 | 2020-12-31 | $1.23 | $1.24 | -$0.89 | −41.98% |
| Q3 2020 | 2020-09-30 | $0.29 | $0.29 | $1.21 | — |
| Q2 2020 | 2020-06-30 | -$2.66 | -$2.66 | -$4.13 | — |
| Q1 2020 | 2020-03-31 | $1.22 | $1.23 | -$0.32 | −20.78% |
| Q4 2019 | 2019-12-31 | $2.12 | $2.13 | $2.12 | — |
| Q3 2019 | 2019-09-30 | -$0.92 | -$0.92 | -$2.52 | — |
| Q2 2019 | 2019-06-30 | $1.47 | $1.48 | $0.08 | +5.76% |
| Q1 2019 | 2019-03-31 | $1.54 | $1.55 | $0.37 | +31.62% |
| Q4 2018 | 2018-12-31 | $0.00 | $0.00 | $2.96 | — |
| Q3 2018 | 2018-09-30 | $1.60 | $1.62 | -$0.46 | −22.33% |
| Q2 2018 | 2018-06-30 | $1.39 | $1.40 | -$0.94 | −40.34% |
| Q1 2018 | 2018-03-31 | $1.17 | $1.18 | -$0.88 | −42.93% |
| Q4 2017 | 2017-12-31 | -$2.96 | -$2.96 | -$5.30 | — |
| Q3 2017 | 2017-09-30 | $2.06 | $2.08 | -$0.43 | −17.27% |
| Q2 2017 | 2017-06-30 | $2.33 | $2.35 | -$0.25 | −9.69% |
| Q1 2017 | 2017-03-31 | $2.05 | $2.07 | -$0.48 | −18.97% |
| Q4 2016 | 2016-12-31 | $2.34 | $2.36 | -$0.84 | −26.42% |
| Q3 2016 | 2016-09-30 | $2.49 | $2.52 | -$0.57 | −18.63% |
| Q2 2016 | 2016-06-30 | $2.58 | $2.62 | -$0.34 | −11.64% |
| Q1 2016 | 2016-03-31 | $2.53 | $2.58 | -$0.23 | −8.33% |
| Q4 2015 | 2015-12-31 | $3.18 | $3.26 | $1.00 | +45.87% |
| Q3 2015 | 2015-09-30 | $3.06 | $3.14 | $1.39 | +83.23% |
| Q2 2015 | 2015-06-30 | $2.92 | $3.05 | $0.72 | +32.73% |
| Q1 2015 | 2015-03-31 | $2.76 | $2.91 | $1.43 | +107.52% |
| Q4 2014 | 2014-12-31 | $2.18 | $2.32 | $1.71 | +363.83% |
| Q3 2014 | 2014-09-30 | $1.67 | $1.80 | $1.20 | +255.32% |
| Q2 2014 | 2014-06-30 | $2.20 | $2.39 | $1.74 | +378.26% |
| Q1 2014 | 2014-03-31 | $1.33 | $1.45 | $0.90 | +209.30% |
| Q4 2013 | 2013-12-31 | $0.47 | $0.52 | $0.00 | 0.00% |
| Q3 2013 | 2013-09-30 | $0.47 | $0.51 | $0.04 | +9.30% |
| Q2 2013 | 2013-06-30 | $0.46 | $0.51 | $0.00 | 0.00% |
| Q1 2013 | 2013-03-31 | $0.43 | $0.47 | $0.15 | +53.57% |
| Q4 2012 | 2012-12-31 | $0.47 | $0.50 | $0.04 | +9.30% |
| Q3 2012 | 2012-09-30 | $0.43 | $0.45 | -$0.04 | −8.51% |
| Q2 2012 | 2012-06-30 | $0.46 | $0.47 | -$0.01 | −2.13% |
| Q1 2012 | 2012-03-31 | $0.28 | $0.29 | -$0.12 | −30.00% |
| Q4 2011 | 2011-12-31 | $0.43 | $0.44 | $0.05 | +13.16% |
| Q3 2011 | 2011-09-30 | $0.47 | $0.48 | $0.05 | +13.25% |
| Q2 2011 | 2011-06-30 | $0.47 | $0.48 | $0.07 | +18.99% |
| Q1 2011 | 2011-03-31 | $0.40 | $0.41 | -$0.06 | −13.04% |
| Q4 2010 | 2010-12-31 | $0.38 | $0.39 | -$0.05 | −12.64% |
| Q3 2010 | 2010-09-30 | $0.42 | $0.43 | $0.05 | +15.28% |
| Q2 2010 | 2010-06-30 | $0.40 | $0.41 | $0.09 | +29.51% |
| Q1 2010 | 2010-03-31 | $0.46 | $0.48 | $0.15 | +46.03% |
| Q4 2009 | 2009-12-31 | $0.44 | $0.45 | — | — |
| Q3 2009 | 2009-09-30 | $0.36 | $0.38 | $0.10 | +38.46% |
| Q2 2009 | 2009-06-30 | $0.31 | $0.32 | $0.08 | +35.56% |
| Q1 2009 | 2009-03-31 | $0.32 | $0.33 | — | — |
| Q3 2008 | 2008-09-30 | $0.26 | $0.27 | — | — |
| Q2 2008 | 2008-06-30 | $0.23 | $0.24 | — | — |
Gilead Sciences diluted eps trends
Over the last five fiscal years, Gilead Sciences's diluted eps increased from $0.10 to $6.78, a change of $6.68. The latest reported quarter, Q2 2026, shows -$8.45.
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...